EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b), AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES – OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Plus Therapeutics, Inc. for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on March 31, 2025, (the “Report”), Marc H. Hedrick, as President & Chief Executive Officer of Plus Therapeutics, Inc., and Andrew Sims, as Chief Financial Officer of Plus Therapeutics, Inc., each hereby certifies, respectively, that:

1.
The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934.
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Plus Therapeutics, Inc.

 

 

 

By:

 

/s/ Marc H. Hedrick, MD

Dated: March 31, 2025

 

 

 

Marc H. Hedrick, MD

 

 

 

 

President & Chief Executive Officer

 

 

 

 

 

 

 

By:

 

/s/ Andrew Sims

Dated: March 31, 2025

 

 

 

Andrew Sims

 

 

 

 

Chief Financial Officer